Bispham Barbara Harlin 4

What Happened

• Barbara Bispham, General Counsel and Corporate Secretary of Crescent BioPharma (CBIO), sold 1,218 shares on June 22, 2026. The weighted-average sale price was $17.99, generating proceeds of approximately $21,912.
• This was a sale (not a purchase) and was executed to satisfy tax withholding related to the vesting of restricted stock units — not an independent investment decision.

Key Details

• Transaction date: June 22, 2026; Form 4 filed June 23, 2026 (timely filing).
• Transaction type: Sale (S); shares sold: 1,218; weighted-average price: $17.99; proceeds ≈ $21,912.
• Price range: shares sold in multiple trades at $16.88 to $18.86 (weighted average reported).
• Purpose/footnote: Shares were automatically sold to cover tax withholding for RSUs granted Dec 15, 2025; sales effected under a Rule 10b5-1 plan adopted Feb 25, 2026.
• Shares owned after transaction: Not disclosed in this Form 4.

Context

• These sales were tax-withholding dispositions following RSU vesting and were carried out under a preplanned 10b5-1 instruction — commonly considered routine and not necessarily indicative of the insider’s view on the company’s prospects.
• For retail investors: purchases are usually more informative about insider sentiment; routine tax-related sales like this are common and generally neutral in isolation.